Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
BMC Public Health
Published in: BMC Public Health 1/2024

Open Access 01-12-2024 | Parkinson's Disease | Research

Trends in parkinson’s disease mortality in China from 2004 to 2021: a joinpoint analysis

Authors: Suxian Wang, Shuai Jiang, Jian Wu, Yudong Miao, Yanran Duan, Zihan Mu, Jing Wang, Yanyu Tang, Mingzhu Su, Zixu Guo, Xueqing Yu, Yaojun Zhao

Published in: BMC Public Health | Issue 1/2024

Login to get access

Abstract

Background

This study aimed to analyze the trends of Parkinson’s disease (PD) mortality rates among Chinese residents from 2004 to 2021, provide evidence for the formulation of PD prevention and control strategies to improve the quality of life among PD residents.

Methods

Demographic and sociological data such as gender, urban or rural residency and age were obtained from the National Cause of Death Surveillance Dataset from 2004 to 2021. We then analyzed the trends of PD mortality rates by Joinpoint regression.

Results

The PD mortality and standardized mortality rates in China showed an overall increasing trend during 2004–2021 (average annual percentage change [AAPC] = 7.14%, AAPCASMR=3.21%, P < 0.001). The mortality and standardized mortality rate in male (AAPC = 7.65%, AAPCASMR=3.18%, P < 0.001) were higher than that of female (AAPC = 7.03%, AAPCASMR=3.09%, P < 0.001). The PD standardized mortality rates of urban (AAPC = 5.13%, AAPCASMR=1.76%, P < 0.001) and rural (AAPC = 8.40%, AAPCASMR=4.29%, P < 0.001) residents both increased gradually. In the age analysis, the mortality rate increased with age. And the mortality rates of those aged > 85 years was the highest. Considering gender, female aged > 85 years had the fastest mortality trend (annual percentage change [APC] = 5.69%, P < 0.001). Considering urban/rural, rural aged 80–84 years had the fastest mortality trend (APC = 6.68%, P < 0.001).

Conclusions

The mortality rate of PD among Chinese residents increased from 2004 to 2021. Male sex, urban residence and age > 85 years were risk factors for PD-related death and should be the primary focus for PD prevention.
Literature
1.
Auburger G, Klinkenberg M, Drost J, Marcus K, Gordo BM, Kunz SW, et al. Primary skin fibroblasts as a model of Parkinson’s disease. Mol Neurobiol. 2012;46(1):20–7.PubMedCrossRefPubMedCentral
2.
Valadas JS, Vos M, Verstreken P. Therapeutic strategies in Parkinson’s disease: what we have learned from animal models. Ann N Y Acad Sci. 2015;1338:16–37.PubMedCrossRef
3.
4.
Lampropoulos IC, Malli F, Sinani O, Gourgoulianis KI, Xiromerisiou G. Worldwide trends in mortality related to Parkinson’s disease in the period of 1994–2019: analysis of vital registration data from the WHO Mortality Database. Front Neurol. 2022;4(13):956440.CrossRef
5.
Feigin VL, Vos T, Nichols E, Owolabi MO, Carroll WM, Dichgans M, et al. The global burden of neurological disorders: translating evidence into policy. Lancet Neurol. 2020;19(3):255–65.PubMedCrossRef
6.
7.
Ding C, Wu Y, Chen X, Chen Y, Wu Z, Lin Z, et al. Global, regional, and national burden and attributable risk factors of neurological disorders: The Global Burden of Disease study 1990–2019. Front Public Health. 2022;10:952161.PubMedCrossRefPubMedCentral
8.
Dorsey ER, Constantinescu R, Thompson JP, Biglan KM, Holloway RG, Kieburtz K, et al. Projected number of people with Parkinson disease in the most populous nations, 2005 through 2030. Neurology. 2007;68(5):384–6.PubMedCrossRef
9.
GBD 2016 Neurology Collaborators. Global, regional, and national burden of neurological disorders, 1990–2016: a systematic analysis for the global burden of Disease Study 2016. Lancet Neurol. 2019;18(5):459–80.CrossRef
10.
Rong S, Xu G, Liu B, Sun Y, Snetselaar LG, Wallace RB et al. Trends in Mortality from Parkinson Disease in the United States, 1999–2019. Neurology,2021;97(20):e1986–93.
11.
Ye H, Robak LA, Yu M, Cykowski M, Shulman JM. Genetics and Pathogenesis of Parkinson’s syndrome. Annu Rev Pathol. 2023;18:95–121.PubMedCrossRef
12.
13.
Watt KJC, Meade RM, Williams RJ, Mason JM. Library-Derived peptide aggregation modulators of Parkinson’s Disease Early-Onset α-Synuclein variants. ACS Chem Neurosci. 2022;13(12):1790–804.PubMedCrossRef
14.
Mackenbach JP, Karanikolos M, Looman CW. The rise of mortality from mental and neurological diseases in Europe, 1979–2009: observational study. BMC Public Health. 2014;14:840.PubMedCrossRefPubMedCentral
15.
Chen F, Chen S, Si A, Luo Y, Hu W, Zhang Y, Ma J. The long-term trend of Parkinson’s disease incidence and mortality in China and a bayesian projection from 2020 to 2030. Front Aging Neurosci. 2022;14:973310.PubMedCrossRefPubMedCentral
16.
Zheng Z, Zhu Z, Zhou C, Cao L, Zhao G. Burden of Parkinson Disease in China, 1990–2019: findings from the 2019 global burden of Disease Study. Neuroepidemiology. 2023;57(1):51–64.PubMedCrossRef
17.
Nunez Y, Boehme AK, Li M, Li M, Goldsmith J, Weisskopf MG, et al. Parkinson’s disease aggravation in association with fine particle components in New York State. Environ Res. 2021;201:111554.PubMedCrossRefPubMedCentral
18.
Jo S, Kim YJ, Park KW, Hwang YS, Lee SH, Kim BJ, Chung SJ. Association of NO2 and Other Air Pollution exposures with the risk of Parkinson Disease. JAMA Neurol. 2021;78(7):800–8.PubMedCrossRef
19.
Tanner CM, Kamel F, Ross GW, Hoppin JA, Goldman SM, Korell M, et al. Rotenone, paraquat, and Parkinson’s disease. Environ Health Perspect. 2011;119(6):866–72.PubMedCrossRefPubMedCentral
20.
Pezzoli G, Cereda E, Amami P, Colosimo S, Barichella M, Sacilotto G, et al. Onset and mortality of Parkinson’s disease in relation to type II diabetes. J Neurol. 2023;270(3):1564–72.PubMedCrossRef
21.
Domenighetti C, Sugier PE, Sreelatha AAK, Schulte C, Grover S, Mohamed O, et al. Dairy intake and Parkinson’s Disease: a mendelian randomization study. Mov Disord. 2022;37(4):857–64.PubMedCrossRef
22.
Okubo H, Miyake Y, Sasaki S, Murakami K, Tanaka K, Fukushima W, et al. Dietary patterns and risk of Parkinson’s disease: a case-control study in Japan. Eur J Neurol. 2012;19(5):681–8.PubMedCrossRef
23.
Timblin H, Rahmani E, Ryczek CA, Hill CR, Jones JD. Physical inactivity links depressive symptoms and cognitive functioning among individuals with Parkinson’s disease. Neuropsychology. 2022;36(6):505–12.PubMedCrossRefPubMedCentral
24.
Johansson ME, Cameron IGM, Van der Kolk NM, de Vries NM, Klimars E, Toni I, et al. Aerobic Exercise alters brain function and structure in Parkinson’s Disease: a Randomized Controlled Trial. Ann Neurol. 2022;91(2):203–16.PubMedCrossRefPubMedCentral
25.
Ulivelli M, BezziniD, Kundisova L, Grazi I, Battaglia MA, Nante N, Rossi S. Mortality of Parkinson’s disease in Italy from 1980 to 2015. Neurol Sci. 2022;43(6):3603–11.PubMedCrossRef
26.
Solla P, Cannas A, Ibba FC, Loi F, Corona M, Orofino G, et al. Gender differences in motor and non-motor symptoms among sardinian patients with Parkinson’s disease. J Neurol Sci. 2012;323(1–2):33–9.PubMedCrossRef
27.
Gatto NM, Deapen D, Stoyanoff S, Pinder R, Narayan S, Bordelon Y, Ritz B. Lifetime exposure to estrogens and Parkinson’s disease in California teachers. Parkinsonism Relat Disord. 2014;20(11):1149–56.PubMedCrossRef
28.
Fereshtehnejad SM, Zeighami Y, Dagher A, Postuma RB. Clinical criteria for subtyping Parkinson’s disease: biomarkers and longitudinal progression. Brain. 2017;140(7):1959–76.PubMedCrossRef
29.
Doiron M, Langlois M, Dupré N, Simard M. The influence of vascular risk factors on cognitive function in early Parkinson’s disease. Int J Geriatr Psychiatry. 2018;33(2):288–97.PubMedCrossRef
30.
Bakeberg MC, Gorecki AM, Kenna JE, Jefferson A, Byrnes M, Ghosh S, et al. Differential effects of sex on longitudinal patterns of cognitive decline in Parkinson’s disease. J Neurol. 2021;268(5):1903–12.PubMedCrossRefPubMedCentral
31.
Pankratz N, Nichols WC, Uniacke SK, Halter C, Rudolph A, Shults C, et al. Genome screen to identify susceptibility genes for Parkinson’s disease in a sample without parkin mutations. Am J Hum Genet. 2002;71(1):124–35.PubMedCrossRefPubMedCentral
32.
Chen C, Chen T, Hwang Y, Wen Y, Chiu Y, Wu C, et al. Different prevalence rates of Parkinson’s disease in urban and rural areas: a population-based study in Taiwan. Neuroepidemiology. 2009;33(4):350–7.PubMedCrossRef
33.
Totaro R, Marini C, Pistoia F, Sacco S, Russo T, Carolei A. Prevalence of Parkinson’s disease in the L’Aquila district, central Italy. Acta Neurol Scand. 2005;112(1):24–8.PubMedCrossRef
34.
Taba P, Asser T. Prevalence of Parkinson’s disease in Estonia. Acta Neurol Scand. 2002;106(5):276–81.PubMedCrossRef
35.
Horsfall L, Petersen I, Walters K, Schrag A. Time trends in incidence of Parkinson’s disease diagnosis in UK primary care. J Neurol. 2013;260(5):1351–7.PubMedCrossRef
36.
Zhang H, Wang Z, Qi S, Wu J, Li Z, Awareness. Treatment, and Rehabilitation of Elderly with Parkinson’s Disease - China, 2015–2017. China CDC Wkly. 2020;2(15):241–4.PubMedPubMedCentral
37.
Hristova D, Zachariev Z, Mateva N, Grozdev I. Incidence of Parkinson’s disease in Bulgaria. Neuroepidemiology. 2010;34(2):76–82.PubMedCrossRef
38.
39.
Wang X, Zeng F, Jin W-S, Zhu C, Wang Q-H, Bu X-L, et al. Comorbidity burden of patients with Parkinson’s disease and parkinsonism between 2003 and 2012: a multicentre, nationwide, retrospective study in China. Sci Rep. 2017;7(1):1671.PubMedCrossRefPubMedCentral
40.
Okunoye O, Horsfall H, Marston L, Walters K, Schrag A. Mortality of people with Parkinson’s Disease in a large UK-Based Cohort Study: Time trends and Relationship to Disease Duration. Mov Disord. 2021;36(12):2811–20.PubMedCrossRefPubMedCentral
41.
Peretz C, Rozani V, Giladi N, El-Ad B, Tsamir J, Hemo B, Gurevich T. The modifying effect of Age on Survival in Parkinson’s Disease: a Population-based Cohort Study. Neuroepidemiology. 2019;53(1–2):13–9.PubMedCrossRef
42.
Reeve A, Simcox E, Turnbull D. Ageing and Parkinson’s disease: why is advancing age the biggest risk factor? Ageing ResRev. 2014;14(100):19–30.CrossRef
43.
Lenka A, Padmakumar C, Pal PK. Treatment of older Parkinson’s Disease. Int Rev Neurobiol. 2017;132:381–405.PubMedCrossRef
44.
Haaxma CA, Bloem BR, Borm GF, Oyen WJ, Leenders KL, Eshuis S, Booij J, Dluzen DE, Horstink MW. Gender differences in Parkinson’s disease. J Neurol Neurosurg Psychiatry. 2007;78(8):819–24.PubMedCrossRef
45.
Georgiev D, Hamberg K, Hariz M, Forsgren L, Hariz GM. Gender differences in Parkinson’s disease: a clinical perspective. Acta Neurol Scand. 2017;136(6):570–84.PubMedCrossRef
46.
Dahodwala N, Shah K, He Y, Wu SS, Schmidt P, Cubillos F, Willis AW. Sex disparities in access to caregiving in Parkinson disease. Neurology. 2018;90(1):e48–54.PubMedCrossRefPubMedCentral
47.
Peacock D, Baumeister P, Monaghan A, Siever J, Yoneda J, Wile D. Perception of Healthcare Access and Utility of Telehealth among Parkinson’s Disease patients. Can J Neurol Sci. 2020;47(5):700–4.PubMedCrossRef
Metadata
Title
Trends in parkinson’s disease mortality in China from 2004 to 2021: a joinpoint analysis
Authors
Suxian Wang
Shuai Jiang
Jian Wu
Yudong Miao
Yanran Duan
Zihan Mu
Jing Wang
Yanyu Tang
Mingzhu Su
Zixu Guo
Xueqing Yu
Yaojun Zhao
Publication date
01-12-2024
Publisher
BioMed Central
Published in
BMC Public Health / Issue 1/2024
Electronic ISSN: 1471-2458
DOI
https://doi.org/10.1186/s12889-024-18532-8

Other articles of this Issue 1/2024

BMC Public Health 1/2024 Go to the issue

Research

Mood profile in men and women of all ages is improved by leisure-time physical activity rather than work-related physical activity

Research

Systematic review of Aboriginal and Torres Strait Islander peoples’ experiences and supportive care needs associated with cancer

Research

Dietary carotenoids intake and sex differences in relation to chronic kidney disease a cross-sectional assessment in the NHANES study

Research

A comparison between antibiotic utilisation in public and private community healthcare in Malaysia

Research

Prevalence and predictors of iron deficiency anaemia among children with sickle cell disease in Dodoma, Tanzania: a cross-sectional study

Study Protocol

Multifaceted ORganizational InterventiONs (M-ORION) project for prevention of depression and anxiety among workers: study protocol for a five-arm cluster randomized controlled trial